Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cost-effective treatment of depression with selective serotonin reuptake inhibitors
Autore:
Panzarino, PJ; Nash, DB;
Indirizzi:
Cedars Sinai Med Ctr, Dept Psychiat & Mental Hlth, Los Angeles, CA 90048 USA Cedars Sinai Med Ctr Los Angeles CA USA 90048 , Los Angeles, CA 90048 USA Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA Thomas Jefferson Univ Philadelphia PA USA 19107 hiladelphia, PA 19107 USA Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA Thomas Jefferson Univ Hosp Philadelphia PA USA 19107 elphia, PA 19107 USA
Titolo Testata:
AMERICAN JOURNAL OF MANAGED CARE
fascicolo: 2, volume: 7, anno: 2001,
pagine: 173 - 184
SICI:
1088-0224(200102)7:2<173:CTODWS>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEALTH MAINTENANCE ORGANIZATION; PRIMARY-CARE PATIENTS; QUALITY-OF-LIFE; ANTIDEPRESSANT TREATMENT; TRICYCLIC ANTIDEPRESSANTS; MAJOR DEPRESSION; PHARMACOECONOMIC EVALUATION; ECONOMIC-EVALUATION; TREATMENT OUTCOMES; ANXIETY DISORDERS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
83
Recensione:
Indirizzi per estratti:
Indirizzo: Panzarino, PJ Cedars Sinai Med Ctr, Dept Psychiat & Mental Hlth, 8730 Alden Dr,Suite TH-C306, Los Angeles, CA 90048 USA Cedars Sinai Med Ctr 8730 Alden Dr,Suite TH-C306 Los Angeles CA USA 90048
Citazione:
P.J. Panzarino e D.B. Nash, "Cost-effective treatment of depression with selective serotonin reuptake inhibitors", AM J M CARE, 7(2), 2001, pp. 173-184

Abstract

Objective: To compare factors that influence cost of antidepressant therapy between older tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) and among drugs in the SSRI class. Study Design: Literature review. Results: Pharmacoeconomic data from the primary care and managed care settings demonstrate that the higher acquisition cost of the SSRIs is offset byreduced medical utilization because of a lower incidence of treatment-related adverse events, drug switching, and dosage adjustments than among patients taking TCAs. Analysis of pharmacy claims data suggests that drug acquisition costs, use of concomitant medications, incidence of dose titration, frequency of multitablet therapy (dose stratification), and duration of therapy are the key factors in determining the cost of SSRI therapy. Among the established SSRIs, drug acquisition costs are lowest for paroxetine and sertraline. Costs for concomitant medications may vary by healthcare plan. Recent reports indicate that paroxetine is associated with a low incidence of dose titration. Paroxetine and sertraline are available in extended dosage forms to reduce the need for multitablet therapy. Duration of therapy with all SSRIs is typically shorter than recommended. Conclusion: Antidepressant therapy with SSRIs has been shown to be more cost effective than treatment with TCAs when overall healthcare utilization and expenses are considered.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 12:59:01